Breast Cancer Clinical Roundup

News Articles

(Pfizer) Oct 9, 2020 - The German Breast Group and Pfizer Inc. today announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have...
(FDA in Brief) Oct 7, 2020 - “Today, the U.S. Food and Drug Administration issued draft guidance encouraging the inclusion of premenopausal women in breast cancer clinical trials that investigate the efficacy of hormonal drug and biological products.” "When finalized, the guidance will provide recommendations for industry to...
(EBCC 12) Oct 3, 2020 - Final results of nine-year survival outcomes from NeoALTTO BIG-06 trial for patients with HER2-positive breast cancer.
(Markets Insider) Oct 2, 2020 - Study in over 500 patients with node-negative or node-positive disease highlights impact of the test on treatment decisions, reducing potential over- and under-treatment and leading to a 23.5% net reduction in chemotherapy recommendations.
View all breast cancer news

News Commentary

Editor Image
The finding that atezolizumab is beneficial only with Abraxane and NOT...
Editor Image
The results of the NALA trial were presented earlier and led to the approval of...

Clinical Briefs

At ESMO Virtual Congress 2020, the results from two randomized phase 3 trials monarchE and ASCENT showed that success is possible for breast cancer subtypes that have long eluded treatment. However, the results of IMpassion131, IMpassion130, and IMpassion031 for atezolizumab were a mixed bag.

Featured Breast Cancer Tweets

Kelly K. Hunt, MD
KellyKhunt - Oct 06  @SyedAAhmad5 @kprgrl3 @JaimeDLewisMD @clarongamd It will certainly make the dissection much easier with improved vi… https://t.co/0tefvTMBQE

Julie R. Gralow, MD
jrgralow - Oct 06  Delaying Radiation Therapy While Remaining On Hormone Therapy Until COVID-19 Cases Subside Unlikely To Impact Survi… https://t.co/E7GUce7ULA

Hope S. Rugo, MD
hoperugo - Oct 03  What we showed: prior chemotherapy impacts the survival benefit of CDK4/6i added to fulvestrant. Paloma 3 is the on… https://t.co/Oawl9pI7p7